Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety study of allogeneic iPSC-derived retinal sheet transplantation for retinitis pigmentosa
jRCTa050200027Completed
- Sponsor
- Sumitomo Pharma
- Start
- Oct 2020
- Countries
- 1
01
Overview
Open-label, single-arm trial in retinitis pigmentosa (RP), sponsored by Sumitomo Pharma. Primary endpoints: Increase in retinal thickness and Safety of allogeneic iPSC-retinal sheets. Started Oct 2020; status: completed.
02
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on jRCTa050200027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTa050200027.